CTRI/2025/07/091602Not yet recruitingNot Applicable
An Open Label, Non-Randomized, Single-Arm, Clinical Study to Evaluate the Efficacy and Safety of a Test Regime in Adult Male Participants with Mild to Moderate Alopecia.
Anveya Living Private Limited1 site in 1 country50 target enrollmentStarted: July 30, 2025Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Instrumental assessment of Hair thickness and Hair growth rate
Study Overview
Brief Summary
This is an open label, non-randomized, single-arm, clinical study to evaluate the efficacy and safety of a test regime (Topical Serum + Men’s Hair growth Supplement + Men’s DHT Blocker Supplement) in adult male participants with mild to moderate alopecia.
The potential participants will be screened as per the inclusion and exclusion criteria only after obtaining written informed consent from the participants.
All eligible participants will undergo instrumental assessments, dermatological assessments, laboratory assessments (blood tests) and subjective assessment. Safety will be assessed throughout the study by monitoring adverse events and changes in vital signs (Body temperature, Pulse rate and Blood pressure).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Masking
- None
Eligibility Criteria
- Ages
- 40.00 Year(s) to 60.00 Year(s) (—)
- Sex
- Male
Inclusion Criteria
- •Adult male participants between the ages of 40 to 60 years (both inclusive) at the time of consent.
- •Participants with Norwood Pattern II to IV of hair loss.
- •Participants who are experiencing hair thinning or excessive shedding for at least 3–6 months.
- •Participants with minimum hair length of 2 inches.
- •Participants having good general health as determined by the Investigator on the basis of medical history and vital signs.
Exclusion Criteria
- •Participants with clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia or advanced pattern hair loss.
- •Participants with scalp hair loss at the treatment area, due to disease, injury, or medical therapy.
- •Participants with history of any dermatological condition (like psoriasis or infections) of the scalp other than hair loss OR with any active scalp disease which may interfere in the study.
- •Participants with any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures.
- •Participants with a history of chronic health conditions (eg, diabetes, hypertension, chronic renal failure, heart and liver disease), endocrine abnormalities including stable thyroid disease, psychiatric illness, bariatric surgery/eating disorders such as bulimia or binge eating, cardiovascular surgery, or history of any other major surgery.
- •Participants with the history of malignancy OR known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders.
- •Participants with known allergy or sensitivity to cosmetic products and/or any ingredients of the test product.
- •Participants who had undergone chemotherapy or radiation within the last 2 years.
- •Participants who have undergone hair regrowth treatments (minoxidil, finasteride, PRP, etc.) within 6 months before screening.
- •Participants using anti-androgenic therapies or using low-level lasers for hair growth within 3 months.
- •Participants who have applied topical treatment for hair loss for at least 4 weeks and any systemic treatment for at least 3 months, prior to their participation in the study.
- •Participants with a history or presence of significant alcoholism or drug abuse and smoking or consumption of tobacco products.
Outcomes
Primary Outcomes
Instrumental assessment of Hair thickness and Hair growth rate
Time Frame: Day 00, Day 45 and Day 90
Secondary Outcomes
- Clinical assessment of anagen and telogen ratio (A:T ratio), hair fall, hair strength, hair and scalp related parameters(Day 00, Day 45 and Day 90)
- Instrumental assessment of hair density.(Day 00, Day 45 and Day 90)
- Laboratory assessments of hormonal and nutritional blood markers(Day 00 and Day 90)
- Participant Evaluation Questionnaire(Day 45 and Day 90)
Investigators
Dr Bhagirath Patel
Cliantha Research
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
A study to evaluate the efficacy of test regime in adult females suffering from hair loss.CTRI/2025/07/090415Anveya Living Private Limited50
Not yet recruiting
Not Applicable
A study to evaluate the efficacy of test regime in lactating females with hair fall.CTRI/2025/07/090485ANVEYA LIVING PRIVATE LIMITED50
Not yet recruiting
Phase 1
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric CancerNCT07333573Shanghai Zhongshan Hospital42
Recruiting
Not Applicable
Retrograde Ascending Dissection: Intraluminal Aortic TherapyNCT07405242Ruijin Hospital149
Recruiting
Not Applicable
Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood CirculationNCT07446088Ceragem Clinical Inc.40